Scion Team Page Image


United by our conviction in the power of therapeutic innovation to improve human health.

Meet the Scion team

The ten companies our team has been part of founding or building over the past ten years have realized uncommon success and, together, have given rise to >15 clinical-stage therapeutics, advanced six promising therapeutics into pivotal clinical trials and have generated >$14 billion in combined public equity value and announced M&A proceeds. We are excited to discover what the future holds.

Tadd Headshot 01 Hayden

Tadd Wessel

Managing Partner

Tadd Wessel is the founder and Managing Partner of Petrichor, a private investment firm focused on the healthcare sector. He is also a founder and Managing Partner of Scion. Tadd has more than 25 years of experience, primarily focused on investing and building companies the life sciences sectors. Previously, he was a Partner at OrbiMed Advisors, where he led the build-out of the structured investment business. Prior to OrbiMed, Tadd was a Vice President at Fortress Investment Group focused on healthcare investments. Tadd began his career in the life sciences investment banking groups at Citigroup and Robertson Stephens.

Tadd has served on more than 30 boards most recently including Aurion Biotech, Cryoport (NASDAQ: CYRX), and ITM. He also serves on the Advisory Board of the AIM at Melanoma Foundation, whose mission is dedicated to finding more effective treatments and, ultimately, the cure for melanoma. He also serves on the Board of the International Centers for Precision Oncology (ICPO) whose mission is to scale access of molecularly targeted precision oncology diagnostics and therapeutics for the benefit of cancer patients globally.

Tadd holds an AB in biology from Princeton University.